% | $
Quotes you view appear here for quick access.

Amarantus Bioscience Holdings, Inc Message Board

  • helperwatson helperwatson Dec 30, 2013 6:30 PM Flag


    I spoke a while back of a challenge with BD and other players in bidding fights for Lympro. One has to know that the geriatric market for Lympro is heavily reliant on governmental reimbursement. I discussed this last year and early this year. BD is not always government friendly, they like high margins and risk getting denial of reimbursment and forcing private pay, much like Lympro's counter seeking EMEA approval. Word is out of these fights internally to price the product correctly to the market. Uplisting will come by reverse split after Lympro deal is done, guessing a 6:1 to meet $3pps. Gerald has weeks to finalize or jeopardizes time to market, a serious implication if they don't go it alone. Companies need time to market the product in order to meet EPS guidance to justify the BOD approval for bid on such product. This all means a lot when the BD BOD doesn't want to pay what AMBS wants. There's no doubt BD has first right of refusal due to relationship at this point, but know that the more hands that get in and bid and back down, all start buying into the mcap projection with care in the scientific world. Much like large banks price-fix retail or other industry stocks, the pharma industry does much of the same. This is why it's consistently moving up slowly each day. The word is the 20th was the last key meeting and it's highly suspected that a deal will be announced within the next two weeks. This can place the immediate valuation at well over a 400-500m mcap in days once the news breaks based on what I figure Lympro is going for with cash up front and royalties. Best to all and you haven't seen anything yet in my opinion. Congrats to longs for your faith in the science.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.034+0.004(+15.25%)Oct 21 3:52 PMEDT